
Semaglutide (Injectable) in Wyoming
Doctor-prescribed Semaglutide (Injectable) for Wyoming residents. Reviewed by licensed Wyoming physicians, compounded at FDA-registered pharmacies, and shipped to your door.
All-in monthly price
No membership fee · this is the full price · free shipping · avg 4-week supply
Add in-depth bloodwork
Optional — add a physician-reviewed at-home blood panel to your plan.
Your sex-hormone baseline plus the safety markers that matter on therapy — blood counts, liver and kidney function — from one painless upper-arm device. Matched to your sex (PSA for men; progesterone & FSH for women). No needle, no clinic, physician-reviewed.
This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.

Reviewed by Dr. Gene, MD · Board-certified Family Medicine
Every Pepti prescription is reviewed by a licensed U.S. physician before it's dispensed — and only provided if clinically appropriate.
How it works in Wyoming
- 1Complete a free online intake (~5 minutes).
- 2A licensed Wyoming physician reviews your case within 24 hours.
- 3Your prescription ships from our FDA-registered compounding pharmacy.
- 4Free shipping arrives 2–4 business days later. Refills ship automatically when your supply runs out — cancel anytime.
What Semaglutide (Injectable) does
GLP-1 receptor agonist prescribed for medical weight management under licensed physician supervision. Compounded; not FDA-approved.
Strength is compounded to the exact dose your physician prescribes and stepped up over time; paired with B6 to ease nausea.
Amounts shown are per unit. Compounded fresh at a US FDA-registered pharmacy.
Quality
Every batch independently tested
Every medication batch dispensed through Pepti is independently tested by a qualified third-party laboratory for applicable quality and safety standards before the pharmacy releases it. Batches are tested to the same standard used by 503B outsourcing facilities.
Sterility
USP <71>Confirms the finished preparation is free of viable microorganisms.
Bacterial endotoxins
USP <85>Screens for endotoxins that can cause fever or inflammatory reactions.
Potency
AssayVerifies the labeled concentration of the active peptide is what is in the vial.
Purity
HPLCChecks the active peptide against impurities and degradation products.
Identity
Mass spectrometryConfirms the peptide in the vial is the correct molecule.
pH
USP <791>Confirms the solution sits within the range specified for injection.
Particulate matter
USP <788>Checks the finished vial for visible and sub-visible particles.
Container closure integrity
USP <1207>Confirms the vial seal holds so sterility is maintained through the beyond-use date.
Recent lots
- Lot 100526-SEM-1
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
99.2%
- Lot 100526-SEM-2
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
98.7%
- Lot 100526-SEM-2.5
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
99.2%
Telemedicine in Wyoming.
Wyoming permits telemedicine prescribing under Wyoming Board of Medicine rules. A Wyoming-licensed physician can establish the patient relationship through online intake review for non-controlled medications. Pepti is available in all 50 states and Washington, D.C.
Wyoming's dispersed population makes telehealth a primary access path for specialty care.
Wyoming cities Pepti serves
Your protocol
How Semaglutide is prescribed in Wyoming.
Who it's for
- Adults with a BMI in the range their physician considers appropriate for GLP-1 therapy
- Patients who have struggled with appetite and weight despite diet and exercise
- People who want physician-managed dose escalation rather than a fixed dose
- Patients already on semaglutide who want to continue at their current dose
Your physician decides whether Semaglutide is appropriate for you after reviewing your intake and labs.
Directions & duration
Inject 0.25 mL (25 units) subcutaneously once weekly.
What's included
- Licensed physician review of your intake, history, and labs
- Medication compounded to your prescription by a PCAB-accredited, FDA-registered pharmacy
- Every batch independently tested before release
- Sterile syringes and alcohol prep pads for injectables
- Tracked delivery to your door, refills on schedule
- Message your physician anytime; dose changes without an appointment
Storage & handling
- Store refrigerated (36–46°F / 2–8°C) at all times, including before first use.
- One vial is your monthly supply. A fresh vial ships to your Wyoming address every 28 days on your refill schedule, so you're always well inside the beyond-use date on your label.
- Protect from light. Wipe the stopper with an alcohol pad before every draw.
- Dispose of syringes in the sharps container per the included instructions.
What to expect
A typical course of Semaglutide in Wyoming.
The science
How Semaglutide works, and what the research shows.
How it works
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone.
It slows gastric emptying, reduces appetite at the hypothalamic level, and improves insulin sensitivity.
Clinical trials show 15-20% body weight loss over 68 weeks.
Clinical evidence
The landmark STEP 1 trial randomized 1,961 adults with obesity to weekly subcutaneous semaglutide 2.4 mg vs placebo.
Wilding et al., NEJM 2021After 68 weeks, the semaglutide arm achieved a mean weight loss of 14.9% of body weight compared to 2.4% on placebo.
The SUSTAIN program demonstrated significant HbA1c reduction in type 2 diabetes, and the SELECT trial extended the evidence to cardiovascular outcomes — semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease.
2023Compounded semaglutide uses the identical active pharmaceutical ingredient prepared by FDA-registered 503A pharmacies.
References
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · New England Journal of Medicine (2021) · PMID 33567185
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) · New England Journal of Medicine (2023) · PMID 37952131
- Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3) · JAMA (2021) · PMID 33625476
- Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial · JAMA (2021) · PMID 33755728
- Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine (2016) · PMID 27633186
- Davies M, Færch L, Jeppesen OK, et al.. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial · The Lancet (2021) · PMID 33667417
- Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial · Nature Medicine (2022) · PMID 36216945
- Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial · JAMA (2022) · PMID 35015037
- Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) · New England Journal of Medicine (2025) · PMID 40353578
- Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) · New England Journal of Medicine (2025) · PMID 40305708
- Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension · Diabetes Obes Metab (2022) · PMID 35441470
- Batsis JA, Gavras A, Gross DC, Cheever CR, Da Silva BR et al.. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review · Ann Intern Med (2026) · PMID 41996180
- Pasternak B, Wintzell V, Hviid A et al.. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study · BMJ (2024) · PMID 38683947
- Bezin J, Gouverneur A, Pénichon M et al.. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer · Diabetes Care (2023) · PMID 36356111
- Hendershot CS, Bremmer MP, Paladino MB, et al.. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial · JAMA Psychiatry (2025) · PMID 39937469
- Klausen MK, Jensen ME, Møller M, et al.. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial · JCI Insight (2022) · PMID 36066977
- Quddos F, Hubshman Z, Tegge A, et al.. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity · Scientific Reports (2023) · PMID 38017205
- Wang W, Volkow ND, Berger NA, et al.. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population · Nature Communications (2024) · PMID 38806481
- Lähteenvuo M, Tiihonen J, Solismaa A, et al.. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder · JAMA Psychiatry (2025) · PMID 39535805
- Eshraghi R, Ghadimi DJ, Montazerinamin S, et al.. Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis · EClinicalMedicine (2025) · PMID 41324012
- de Faria Moraes B, André Pedral Diniz Leite G, Silveira IB, et al.. Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis · Drug and Alcohol Dependence (2025) · PMID 40845737
- Jensen ME, Klausen MK, Bergmann ML, et al.. Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption · Alcohol, Clinical and Experimental Research (2025) · PMID 40123107
- Hjerpsted JB, Flint A, Brooks A, et al.. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity · Diabetes, Obesity and Metabolism (2018) · PMID 28941314
- Jensterle M, Ferjan S, Ležaič L, et al.. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity · Diabetes, Obesity and Metabolism (2023) · PMID 36511825
- Dahl K, Brooks A, Almazedi F, et al.. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes · Diabetes, Obesity and Metabolism (2021) · PMID 33710717
- Wu KL, Chaikomin R, Doran S, et al.. Artificially sweetened versus regular mixers increase gastric emptying and alcohol absorption · The American Journal of Medicine (2006) · PMID 16945619
- Mitchell MC Jr, Teigen EL, Ramchandani VA. Absorption and peak blood alcohol concentration after drinking beer, wine, or spirits · Alcoholism: Clinical and Experimental Research (2014) · PMID 24655007
- Edelbroek MA, Horowitz M, Wishart JM, et al.. Effects of erythromycin on gastric emptying, alcohol absorption and small intestinal transit in normal subjects · Journal of Nuclear Medicine (1993) · PMID 8455074
- Samokhvalov AV, Rehm J, Roerecke M. Alcohol Consumption as a Risk Factor for Acute and Chronic Pancreatitis: A Systematic Review and a Series of Meta-analyses · EBioMedicine (2015) · PMID 26844279
- Legro RS, Dodson WC, Kris-Etherton PM, et al.. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome · J Clin Endocrinol Metab (2015) · PMID 26401593
- Chen H, Lei X, Yang Z, et al.. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial · Reprod Biol Endocrinol (2025) · PMID 40713699
- Huang KP, Acosta AA, Ghidewon MY, et al.. Dissociable hindbrain GLP1R circuits for satiety and aversion · Nature (2024) · PMID 38987598
- Kanoski SE, Rupprecht LE, Fortin SM, et al.. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide · Neuropharmacology (2012) · PMID 22227019
- Orsama AL, Mattila E, Ermes M, van Gils M et al.. Weight rhythms: weight increases during weekends and decreases during weekdays · Obes Facts (2014) · PMID 24504358
- Steinberg DM, Bennett GG, Askew S, Tate DF. Weighing every day matters: daily weighing improves weight loss and adoption of weight control behaviors · J Acad Nutr Diet (2015) · PMID 25683820
- Ross R, Neeland IJ, Yamashita S, Shai I et al.. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity · Nat Rev Endocrinol (2020) · PMID 32020062
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity · Diabetes Obes Metab (2021) · PMID 33269530
- Tronieri JS, Allison KC, DeRouen K, et al.. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial · American Journal of Clinical Nutrition (2026) · PMID 42323166
- Frid AH, Kreugel G, Grassi G, Halimi S, et al.. New Insulin Delivery Recommendations · Mayo Clin Proc (2016) · PMID 27594187
- Wang K, Zhang S, Liu C, Chen Y. A meta-analysis and meta-regression on the prevalence of lipohypertrophy in diabetic patients on insulin therapy · Therapie (2021) · PMID 33958198
- Chen L, Xing Q, Li J, Zhou J. Injection Technique Education in Patients with Diabetes Injecting Insulin into Areas of Lipohypertrophy: A Randomized Controlled Trial · Diabetes Ther (2021) · PMID 33570716
- Malgave A, Akbar S, Joseph A, Dande Aishwarya, Peraman R, Malayandi R. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery · Eur J Pharm Biopharm (2025) · PMID 40490042
- Akbar S, Malgave A, Joseph A, Kumar A, Malayandi R. Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation · Pharm Res (2026) · PMID 42086873
- Benet A, Halseth T, Kang J, Kim A, Ackermann R, Srinivasan S, Schwendeman S, Schwendeman A. The Effects of pH and Excipients on Exenatide Stability in Solution · Pharmaceutics (2021) · PMID 34452224
- Kopp KL, Lamberth K, Schelde O, et al.. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists · Pharmaceutical Research (2026) · PMID 42533250
- Belcourt J, Sapowadia A, White CM, et al.. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown · The Annals of Pharmacotherapy (2026) · PMID 41689811
- Mohan V, Kalra S, Ahluwalia A, et al.. Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications · Cureus (2026) · PMID 42769283
- Perkovic V, Tuttle KR, Rossing P, et al.. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) · New England Journal of Medicine (2024) · PMID 38785209
- Hathaway JT, Shah MP, Hathaway DB, et al.. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide · JAMA Ophthalmology (2024) · PMID 38958939
- He L, Wang J, Ping F, et al.. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials · JAMA Internal Medicine (2022) · PMID 35344001
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M.. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss · JAMA (2023) · PMID 37796527
- Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R.. Association of semaglutide with risk of suicidal ideation in a real-world cohort · Nature Medicine (2024) · PMID 38182782
- Guo L, Klonoff DC, Al Sifri SN, Bee YM et al.. Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts · Diabetes Research and Clinical Practice (2026) · PMID 42398590
- Plutzky J, Bogdański P, Colhoun HM et al.. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis · Circulation (2026) · PMID 42610271
- Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel · J Clin Pharmacol (2015) · PMID 25475122
- Lau J, Bloch P, Schäffer L, et al.. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide · Journal of Medicinal Chemistry (2015) · PMID 26308095
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide · Frontiers in Endocrinology (2019) · PMID 31031702
- Wharton S, Calanna S, Davies M, et al.. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss · Diabetes, Obesity and Metabolism (2022) · PMID 34514682
- Wharton S, et al.. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial · The Lancet Diabetes & Endocrinology (2025) · PMID 40961952
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery · Nat Rev Drug Discov (2021) · PMID 33536635
- Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions · Bioorg Med Chem (2018) · PMID 28720325
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions · Drug Discov Today (2015) · PMID 25450771
- Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review · Drug Des Devel Ther (2024) · PMID 38952487
- Barenbaum SR, Kumar RB, Aronne LJ. Management of Medication-Induced Weight Gain · Gastroenterology Clinics of North America (2023) · PMID 37919025
- Kumar RB, Aronne LJ. Iatrogenic Obesity · Endocrinology and Metabolism Clinics of North America (2020) · PMID 32418589
- Biondi B. Subclinical Hypothyroidism in Patients with Obesity and Metabolic Syndrome: A Narrative Review · Nutrients (2023) · PMID 38201918
- Murphy C, Koehler K. Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression · Scandinavian Journal of Medicine and Science in Sports (2022) · PMID 34623696
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
PCAB-accredited pharmacies on every order.
Every fulfillment runs through a PCAB-accredited pharmacy.
See the lab results
- Rigorous third-party quality & safety inspections
- Cleanliness and sterile processes
- Proper ingredient sourcing
- Accurate dosing and formulation
- Staff training and procedures
- Accredited by NABP & ACHC
Frequently asked
about Semaglutide (Injectable) in Wyoming.
Yes. Semaglutide (Injectable) is legal when prescribed by a physician licensed in Wyoming and dispensed by an FDA-registered compounding pharmacy. Wyoming permits telemedicine prescribing under Wyoming Board of Medicine rules. A Wyoming-licensed physician can establish the patient relationship through online intake review for non-controlled medications.
Most orders ship from our FDA-registered compounding pharmacy within 1–3 business days after physician approval. Delivery within Wyoming typically arrives 1-3 business days after shipment. Pepti serves patients across Wyoming including Cheyenne, Casper, Laramie, and Gillette.
No. Pepti operates as a fully telehealth platform in Wyoming. Wyoming permits telemedicine prescribing under Wyoming Board of Medicine rules. A Wyoming-licensed physician can establish the patient relationship through online intake review for non-controlled medications.
Semaglutide (Injectable) starts at $99 at Pepti. Pepti is subscription-based — your refill ships when your supply runs out, and you can cancel anytime. Pricing is the same nationwide — no Wyoming-specific markup. Shipping is free.
Yes — Pepti is available in all 50 states and Washington, D.C. Wherever you are in the country, a physician licensed in your state reviews your intake and your medication ships from an FDA-registered compounding pharmacy.
You don't need an in-person peptide clinic — Pepti provides doctor-prescribed Semaglutide (Injectable) entirely online anywhere in Wyoming. A physician licensed in Wyoming reviews your intake, and your medication ships from an FDA-registered compounding pharmacy to your door. Unlike "research use only" peptide sites, every Pepti order requires a valid patient-specific prescription and a licensed dispensing pharmacy.
No. "Research use only" Semaglutide (Injectable) is sold with no prescription, no physician, and no dispensing pharmacy, and is not legally sold for human use — independent testing of research-grade peptides has repeatedly found underdosing, mislabeling, and contamination. Prescription Semaglutide (Injectable) is compounded for you at an FDA-registered US pharmacy after a licensed physician's review. When comparing Semaglutide (Injectable) options in Wyoming, only consider providers that can name their prescribing physicians and their dispensing pharmacy.
33 more questions about Pepti, answered.Show fewer
Pepti serves all of Wyoming. A physician licensed in Wyoming reviews every order within 4 hours, the prescription is compounded by a state-licensed, FDA-registered pharmacy, and it ships free and tracked to any Wyoming street address. The price is the same as every other state.
Yes. The whole process is online in Wyoming: a free assessment, physician review, messaging, dose changes, and refills through your Pepti account or the Hello Pepti app. No clinic visit is required.
Pepti ships Semaglutide to Wyoming directly from the pharmacy: free, tracked, unbranded, in insulated packaging with ice packs for refrigerated medication. The pharmacy compounds in 1-3 business days and delivery takes 1-3 business days after shipment. PO Boxes are not accepted.
Every treatment on Pepti's catalog ships to Wyoming. Eligibility is confirmed during the assessment from your Wyoming shipping address, and if anything ever cannot ship to your address it is refunded.
The same as everywhere Pepti serves: one all-in monthly price per treatment that includes the medication, the physician, and shipping, with no Wyoming-specific markup and no membership or consult fee. Every price is on the product page.
Yes. Pepti's physicians hold licenses in Wyoming, and only a physician licensed where you live reviews and prescribes your order. Their names and credentials are on the providers page.
Yes. Pepti's partner pharmacies are state-licensed, FDA-registered 503A compounding pharmacies licensed to dispense into Wyoming, and every batch is independently tested before it ships.
GLP-1 receptor agonist prescribed for medical weight management under licensed physician supervision. Compounded; not FDA-approved. Semaglutide is prescription-only at Pepti: a licensed physician reviews your assessment and, if appropriate, prescribes it to be compounded by a state-licensed, FDA-registered pharmacy.
Semaglutide is commonly prescribed for: Adults with a BMI in the range their physician considers appropriate for GLP-1 therapy; Patients who have struggled with appetite and weight despite diet and exercise; People who want physician-managed dose escalation rather than a fixed dose; Patients already on semaglutide who want to continue at their current dose. Whether it is appropriate for you is decided by the reviewing physician from your history, medications, and labs where required.
Yes. Semaglutide is prescription-only. The free online assessment takes about five minutes, a physician licensed in Wyoming reviews it within 4 hours, and if approved the prescription goes to the pharmacy. If not approved, the medication charge is refunded.
Yes. Semaglutide is one of the medications Pepti requires recent bloodwork for before it is prescribed. Upload a recent lab report from any lab, or order Pepti's at-home panel; the physician reviews the results with your assessment.
Semaglutide is a subcutaneous injection into the abdomen or thigh with a small insulin syringe. Your kit ships with sterile syringes and alcohol prep pads, and the exact dose and schedule are printed on the pharmacy label. Dosing videos are in your account.
One vial is your monthly supply at the dose your physician prescribes. A fresh vial ships about every 28 days, and the date moves if your physician changes your dose. Store it as the pharmacy label directs, refrigerated.
Once per fill, $99 each time, when the next vial ships. It renews until you cancel, which you can do anytime from your account with no cancellation fee.
The compounded Semaglutide with sterile syringes and alcohol prep pads, free tracked shipping in an unbranded box with insulated packaging, the physician review, ongoing physician care and dose adjustments, and unlimited messaging.
Reported side effects of Semaglutide are usually mild: nausea (most common, especially first 2 weeks); constipation or diarrhea; fatigue; heartburn; reduced appetite (this is the goal). The physician screens your history, medications, and allergies before prescribing, the medication-specific consent lists the known risks, and you can message your physician about anything you notice. Seek emergency care for severe symptoms.
Response varies by person, goal, and dose, and Semaglutide is prescribed for ongoing use rather than a short trial. Your physician sets expectations at approval, tracks how you respond through your account, and adjusts the dose without an appointment.
Yes, one step at a time. Semaglutide moves up the pharmacy's strength ladder when your physician approves, and you pay the cost difference for the higher strength. It is never doubled.
Yes. Add Semaglutide to a plan with another treatment and both go through one assessment and one physician review, shipping together on one schedule. Each keeps its own catalog price. The physician reviews the combination and can adjust it.
Compounded Semaglutide is not FDA-approved. A brand-name form of the active ingredient is FDA-approved for specific indications; Pepti's version is compounded to your physician's prescription by an FDA-registered 503A pharmacy and prescribed off-label.
Yes, when prescribed by a licensed physician and dispensed by a licensed pharmacy, which is how Pepti provides it in Wyoming. Research-use-only Semaglutide sold without a prescription is labeled not for human use and is a different product.
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone. At Pepti it is prescribed to support appetite control, significant weight loss, blood sugar support, cardiovascular health. Individual response varies, and your physician sets expectations at approval.
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone. It slows gastric emptying, reduces appetite at the hypothalamic level, and improves insulin sensitivity. Clinical trials show 15-20% body weight loss over 68 weeks. Compounded Semaglutide is not FDA-approved; it is prescribed off-label by a licensed physician after reviewing your assessment.
Semaglutide is prescribed for appetite control, significant weight loss, blood sugar support, cardiovascular health. It is commonly requested by adults with a BMI in the range their physician considers appropriate for GLP-1 therapy; patients who have struggled with appetite and weight despite diet and exercise; people who want physician-managed dose escalation rather than a fixed dose; patients already on semaglutide who want to continue at their current dose. Whether it is appropriate for you is the reviewing physician's decision.
Semaglutide is studied for appetite control, significant weight loss, blood sugar support, cardiovascular health. Those are the goals it is prescribed to support at Pepti; results vary by person, dose, and consistency, and no outcome is guaranteed. Your physician tracks how you respond through your account.
The landmark STEP 1 trial (Wilding et al., NEJM 2021) randomized 1,961 adults with obesity to weekly subcutaneous semaglutide 2.4 mg vs placebo. After 68 weeks, the semaglutide arm achieved a mean weight loss of 14.9% of body weight compared to 2.4% on placebo. The SUSTAIN program demonstrated significant HbA1c reduction in type 2 diabetes, and the SELECT trial (2023) extended the evidence to cardiovascular outcomes — semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease. Compounded semaglutide uses the identical active pharmaceutical ingredient prepared by FDA-registered 503A pharmacies. References are listed on this page.
Semaglutide is generally not prescribed with: active cancer or history of cancer (unless approved by oncologist); pregnancy or breastfeeding; severe kidney or liver disease; known allergy to the peptide or excipients; personal or family history of medullary thyroid cancer; multiple endocrine neoplasia syndrome type 2; pancreatitis history. The physician screens for these in your intake, and anything that rules Semaglutide out means it is not prescribed and is refunded.
At Pepti. Complete the free assessment, a physician licensed in Wyoming reviews it within 4 hours, and if appropriate Semaglutide is compounded by a state-licensed, FDA-registered pharmacy and shipped free to your door for $99 per month, all-in. Not prescribed means refunded.
Injectable vial: 1 to 3 mL, sized to your dose, containing compounded to your dose Semaglutide. One vial is your monthly supply at the prescribed dose, and a fresh one ships about every 28 days.
Not currently. Semaglutide ships as a multi-dose vial with sterile syringes and prep pads. The pepti Pen is available for 10 other treatments.
$99 per month covers the compounded Semaglutide, the physician review, ongoing physician care including dose adjustments and refill review, unlimited messaging, and free tracked shipping. There is no membership, consult, visit, or refill fee; the only separate charges are optional at-home lab panels and a physician-approved dose increase billed at pharmacy cost.
Yes. Semaglutide is on Pepti's live catalog, which lists only treatments a partner pharmacy can compound and ship today. If a physician prescribes it, it ships; if it ever cannot be dispensed, the charge is refunded.
Semaglutide ships to 50 states, free and tracked, in insulated unbranded packaging. Eligibility is confirmed during the assessment from your shipping address.
Semaglutide (Injectable) in every state
Pepti is available in all 50 states and Washington, D.C.
Pepti operates in Wyoming through licensed physician partnerships. Compounded medications are produced at FDA-registered 503A pharmacies. Treatment decisions are made by your prescribing physician.